PALISADE BIO INC (PALI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PALI • US6963894026

1.73 USD
+0.01 (+0.58%)
At close: Feb 10, 2026
1.77 USD
+0.04 (+2.31%)
After Hours: 2/10/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PALI. PALI was compared to 523 industry peers in the Biotechnology industry. While PALI has a great health rating, there are worries on its profitability. PALI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • PALI had negative earnings in the past year.
  • PALI had a negative operating cash flow in the past year.
  • PALI had negative earnings in each of the past 5 years.
  • In the past 5 years PALI always reported negative operating cash flow.
PALI Yearly Net Income VS EBIT VS OCF VS FCFPALI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • PALI's Return On Assets of -132.70% is on the low side compared to the rest of the industry. PALI is outperformed by 81.26% of its industry peers.
  • The Return On Equity of PALI (-192.71%) is worse than 67.11% of its industry peers.
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROIC N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
PALI Yearly ROA, ROE, ROICPALI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PALI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PALI Yearly Profit, Operating, Gross MarginsPALI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PALI has more shares outstanding
  • The number of shares outstanding for PALI has been increased compared to 5 years ago.
  • The debt/assets ratio for PALI has been reduced compared to a year ago.
PALI Yearly Shares OutstandingPALI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
PALI Yearly Total Debt VS Total AssetsPALI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • An Altman-Z score of 24.19 indicates that PALI is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 24.19, PALI belongs to the top of the industry, outperforming 90.82% of the companies in the same industry.
  • PALI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.19
ROIC/WACCN/A
WACC12.44%
PALI Yearly LT Debt VS Equity VS FCFPALI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

  • A Current Ratio of 3.24 indicates that PALI has no problem at all paying its short term obligations.
  • The Current ratio of PALI (3.24) is worse than 61.38% of its industry peers.
  • PALI has a Quick Ratio of 3.24. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
  • PALI has a Quick ratio (3.24) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
PALI Yearly Current Assets VS Current LiabilitesPALI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • PALI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.15%, which is quite impressive.
  • PALI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PALI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.56% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.78%
EPS Next 2Y40.17%
EPS Next 3Y24.98%
EPS Next 5Y14.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PALI Yearly Revenue VS EstimatesPALI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
PALI Yearly EPS VS EstimatesPALI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50K -100K -150K -200K -250K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PALI. In the last year negative earnings were reported.
  • Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PALI Price Earnings VS Forward Price EarningsPALI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PALI Per share dataPALI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PALI's earnings are expected to grow with 24.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.17%
EPS Next 3Y24.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PALI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PALISADE BIO INC

NASDAQ:PALI (2/10/2026, 8:00:02 PM)

After market: 1.77 +0.04 (+2.31%)

1.73

+0.01 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-23
Inst Owners32.53%
Inst Owner Change2040.15%
Ins Owners0.01%
Ins Owner Change0.51%
Market Cap257.77M
Revenue(TTM)N/A
Net Income(TTM)-14.44M
Analysts84
Price Target13.43 (676.3%)
Short Float %12.78%
Short Ratio3.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)23.66%
Max EPS beat(2)32.15%
EPS beat(4)3
Avg EPS beat(4)12.73%
Min EPS beat(4)-11.13%
Max EPS beat(4)32.15%
EPS beat(8)4
Avg EPS beat(8)3.92%
EPS beat(12)8
Avg EPS beat(12)37.63%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.86%
PT rev (3m)64.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)28.51%
EPS NY rev (3m)44.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 34.41
P/tB 34.41
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z 24.19
F-Score2
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)144.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.62%
EPS Next Y92.78%
EPS Next 2Y40.17%
EPS Next 3Y24.98%
EPS Next 5Y14.56%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.52%
OCF growth 3YN/A
OCF growth 5YN/A

PALISADE BIO INC / PALI FAQ

What is the ChartMill fundamental rating of PALISADE BIO INC (PALI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PALI.


Can you provide the valuation status for PALISADE BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to PALISADE BIO INC (PALI). This can be considered as Overvalued.


How profitable is PALISADE BIO INC (PALI) stock?

PALISADE BIO INC (PALI) has a profitability rating of 0 / 10.


How financially healthy is PALISADE BIO INC?

The financial health rating of PALISADE BIO INC (PALI) is 7 / 10.